Navigation Links
Biocartis Presents the Successful use of Idylla[TM] for the Detection of the BRAF Mutation Status in Tumour Samples at the International AACR Congress (American Association for Cancer Research) in Boston
Date:10/22/2013

MECHELEN, Belgium and LAUSANNE, Switzerland, October 22, 2013 /PRNewswire/ --

Biocartis also introduces IdyllaTM, the brand name for its innovative and high-quality diagnostic platform (previously codenamed Apollo). IdyllaTM is designed to carry out fast and accurate analysis of a broad range of clinical samples[1]. The platform retains the sensitivity of existing technologies but overcomes, amongst others, the current time-consuming testing process of tumour samples.

Apollo becomes IdyllaTM

IdyllaTM is Biocartis' commercial brand name for the fully integrated molecular diagnostic platform, which analyses clinical samples accurately, fast and easily. It gives short shrift to today's time-consuming molecular testing processes. IdyllaTM will provide a direct access to a wide array of tests in various diagnostic areas. Biocartis is currently developing tests primarily in the field of oncology.

Fast and accurate analysis of tumour samples

In collaboration with the world-renowned American MD Anderson Cancer Center, IdyllaTM was used in a comparative study that included various tumour types, for the presence of the BRAF cancer gene.

Today, Dr Janku from MD Anderson and Biocartis presented the results from this study at the international congress of the American Association for Cancer Research AACR-NCI-EORTC (Molecular Targets and Cancer Therapeutics). At this conference, the latest innovations in cancer diagnosis are presented to a large delegation of cancer experts from both the research and clinical/pharmaceutical world. The study was also selected by AACR as one of three studies presented at the AACR press conference today: http://www.aacr.org/home/public--media/aacr-press-releases.aspx?d=3190.

IdyllaTM simply and rapidly detects mutations and shows a much higher sensitivity as compared to standard diagnostic assays and standard sequencing, thereby eliminating the need for dissection of the tumor region. These technologies are available in highly specialised laboratories, where the process from sample to result can take several weeks, whilst IdyllaTM yields a reportable result in 35-90 minutes, depending on the test.

IdyllaTM and first cancer test on the market in second half of 2014

IdyllaTM and the BRAF test will be marketed by Biocartis. The launch of the platform and the BRAF assay in Europe is expected in the second half of 2014.

About Biocartis (http://www.biocartis.com)

Biocartis aspires to improve quality of life by providing direct access to personalized medicine to patients worldwide. Its goal is to advance medical treatment through the broad implementation of state-of-the-art personalized diagnostic tests performed close to the clinical decision-making point.

Biocartis' innovative research and diagnostic systems feature the detection of molecular components, which are indicative for a specific pathological state. The new systems are highly user-friendly, require less hands-on time and minimize the handling of valuable samples, which is of the utmost importance for tumor biopsies. In addition, Biocartis develops assays with major clinical and compelling health economic value. Oncology is Biocartis' primary focus as it represents one of the areas with the greatest unmet needs for personalized medicine.

Biocartis is a rapidly growing business that currently employs close to 200 people. It has offices in Belgium (close to Brussels) and in Switzerland (Lausanne).

[1] Platform and assays are currently under development. For Research Use Only. Not for use in diagnostic procedures.


'/>"/>
SOURCE Biocartis
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Biocartis Strengthens Management Team With Chief Commercial Officer
2. Biocartis versterkt managementteam met commercieel directeur
3. 3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
4. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
5. Adamas Pharmaceuticals Presents Positive Clinical Data For ADS-5102, A Treatment For Levodopa-Induced Dyskinesia, At The World Parkinsons Congress
6. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
7. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
8. ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naive Adults with HIV-1
9. Metabolic Solutions Development Company presents Phase 2a clinical trial results at the 14th International Conference on Alzheimers Drug Discovery
10. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
11. ARUP Laboratories Presents Recent Findings at PAINWeek
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  Cornerstone Pharmaceuticals, Inc., a ... milestone today.  Following successful End-of-Phase I (EOP1) ... and Drug Administration (FDA), the Company has ... path forward to conduct pivotal trials of ... acute myeloid leukemia (AML) and pancreatic cancer. ...
(Date:3/23/2017)... March 23, 2017 Piramal ... Limited, anuncia el nombramiento de Stuart E. ... plataforma de servicios integrados completa para su base ... cargo clave en el crecimiento y ejecución de ... responsable de impulsar todas las actividades de desarrollo ...
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... The ... from the NCQA. The accreditation covers StayWell’s asthma, coronary artery disease, congestive heart ... granted to organizations that have excellent programs for the delivery and improvement of ...
(Date:3/23/2017)... ... March 23, 2017 , ... March 23, 2017 - ... to easily reprint customer invoices, bills, statements and other correspondence when they have ... needed to retrieve and print the documents and batch them for efficient handling. ...
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... March 23, 2017 , ... Corra Group is ... competitive pricing. Verisys through its FACIS and other services maintains the ... actions. , “We are delighted to be able to offer these various products ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April 4, 2017 ... will the new EU MDR language change the way manufacturers approach CERs? ...
Breaking Medicine News(10 mins):